These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 3291449)

  • 41. Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli.
    Ravenscroft N; Haeuptle MA; Kowarik M; Fernandez FS; Carranza P; Brunner A; Steffen M; Wetter M; Keller S; Ruch C; Wacker M
    Glycobiology; 2016 Jan; 26(1):51-62. PubMed ID: 26353918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential virulence of viable but nonculturable Shigella dysenteriae type 1.
    Rahman I; Shahamat M; Chowdhury MA; Colwell RR
    Appl Environ Microbiol; 1996 Jan; 62(1):115-20. PubMed ID: 8572688
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Production of Shiga toxin and other cytotoxins by serogroups of Shigella.
    Bartlett AV; Prado D; Cleary TG; Pickering LK
    J Infect Dis; 1986 Dec; 154(6):996-1002. PubMed ID: 3537154
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genotypic and phenotypic characterization of an aroD deletion-attenuated Escherichia coli K12-Shigella flexneri hybrid vaccine expressing S. flexneri 2a somatic antigen.
    Newland JW; Hale TL; Formal SB
    Vaccine; 1992; 10(11):766-76. PubMed ID: 1441732
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spontaneous tandem amplification and deletion of the shiga toxin operon in Shigella dysenteriae 1.
    McDonough MA; Butterton JR
    Mol Microbiol; 1999 Dec; 34(5):1058-69. PubMed ID: 10594830
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Shigellosis: the current status of vaccine development.
    Kweon MN
    Curr Opin Infect Dis; 2008 Jun; 21(3):313-8. PubMed ID: 18448978
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate.
    McKenzie R; Venkatesan MM; Wolf MK; Islam D; Grahek S; Jones AM; Bloom A; Taylor DN; Hale TL; Bourgeois AL
    Vaccine; 2008 Jun; 26(26):3291-6. PubMed ID: 18468742
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection.
    Altboum Z; Barry EM; Losonsky G; Galen JE; Levine MM
    Infect Immun; 2001 May; 69(5):3150-8. PubMed ID: 11292735
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular evolution of large virulence plasmid in Shigella clones and enteroinvasive Escherichia coli.
    Lan R; Lumb B; Ryan D; Reeves PR
    Infect Immun; 2001 Oct; 69(10):6303-9. PubMed ID: 11553574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Production, characterization and immunodiagnostic application of a monoclonal antibody to Shiga toxin.
    Qadri F; Mohi MG; Azim T; Faruque SM; Kabir AK; Albert MJ
    J Diarrhoeal Dis Res; 1996 Jun; 14(2):95-100. PubMed ID: 8870402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Shigella vaccines.
    Formal SB; Hale TL; Kapfer C
    Rev Infect Dis; 1989; 11 Suppl 3():S547-51. PubMed ID: 2669098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic basis of virulence in Shigella species.
    Hale TL
    Microbiol Rev; 1991 Jun; 55(2):206-24. PubMed ID: 1886518
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of plasmids in virulence-associated attributes and in O-antigen expression in Shigella dysenteriae type 1 strains.
    Haider K; Azad AK; Qadri F; Nahar S; Ciznar I
    J Med Microbiol; 1990 Sep; 33(1):1-9. PubMed ID: 1700125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Shiga and Shiga-like toxins].
    Ciudin L
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1990; 35(1):1-16. PubMed ID: 2173117
    [No Abstract]   [Full Text] [Related]  

  • 55. Role of Escherichia coli K-12 rfa genes and the rfp gene of Shigella dysenteriae 1 in generation of lipopolysaccharide core heterogeneity and attachment of O antigen.
    Klena JD; Ashford RS; Schnaitman CA
    J Bacteriol; 1992 Nov; 174(22):7297-307. PubMed ID: 1385388
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of the Vibrio cholerae irgA gene as a locus for insertion and expression of heterologous antigens in cholera vaccine strains.
    Butterton JR; Boyko SA; Calderwood SB
    Vaccine; 1993 Oct; 11(13):1327-35. PubMed ID: 8296486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. O-specific side-chain toxin-protein conjugates as parenteral vaccines for the prevention of shigellosis and related diseases.
    Robbins JB; Chu C; Watson DC; Szu SC; Daniels EM; Lowe CU; Schneerson R
    Rev Infect Dis; 1991; 13 Suppl 4():S362-5. PubMed ID: 2047664
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Construction of recombinant aroA salmonellae stably producing the Shigella dysenteriae serotype 1 O-antigen and structural characterization of the Salmonella/Shigella hybrid LPS.
    Fält IC; Mills D; Schweda EK; Timmis KN; Lindberg AA
    Microb Pathog; 1996 Jan; 20(1):11-30. PubMed ID: 8692007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterisation of Plesiomonas shigelloides strains that share type-specific antigen with Shigella flexneri 6 and common group 1 antigen with Shigella flexneri spp. and Shigella dysenteriae 1.
    Albert MJ; Ansaruzzaman M; Qadri F; Hossain A; Kibriya AK; Haider K; Nahar S; Faruque SM; Alam AN
    J Med Microbiol; 1993 Sep; 39(3):211-7. PubMed ID: 8366520
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of the SLT-1A toxin operon by a ferric uptake regulatory protein in toxinogenic strains of Shigella dysenteriae type 1.
    Svinarich DM; Palchaudhuri S
    J Diarrhoeal Dis Res; 1992 Sep; 10(3):139-45. PubMed ID: 1430967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.